Unapproved TKIs such as TPX‐0131 and TQ‐B3139 are still under evaluation and recruitment is ongoing for a Phase III clinical study (NCT04009317) to assess TQ‐B3139 vs. crizotinib as first‐line treatment in EML4‐ALK+ NSCLC [28] (Table 1). This evidence concerns the gene EML4 and non-small cell lung carcinoma.